Ocrelizumab Co-formulated With rHuPH20 clinical trials

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis

This study is looking at a new way to give an existing medicine, ocrelizumab, as an injection under the skin for people with Multiple Sclerosis (MS). It aims to check if it's safe and how well people tolerate it, while also learning more about how the medicine works in the body.